Randomized, Non-inferiority Trial Comparing a Dual Maintenance Therapy Strategy With Dolutegravir + Lamivudine (DTG/3TC) or Atazanavir/Ritonavir + Lamivudine (ATV/r+3TC) Versus the Standard WHO First Line Triple Therapy Tenofovir + Lamivudine + Efavirenz (TDF+3TC+EFV) or Dolutegravir + Lamivudine + Tenofovir (DTG+3TC+TDF) in West and Central African HIV-1 Infected Patients
Latest Information Update: 07 Sep 2023
At a glance
- Drugs Atazanavir/ritonavir (Primary) ; Dolutegravir (Primary) ; Lamivudine (Primary) ; Efavirenz/lamivudine/tenofovir
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms MODERATO
- 05 Sep 2023 Planned End Date changed from 20 Dec 2023 to 5 Feb 2025.
- 05 Sep 2023 Planned primary completion date changed from 20 Aug 2023 to 5 Feb 2025.
- 03 May 2023 Status changed from recruiting to active, no longer recruiting.